+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

GSK plc (GSK) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 111 Pages
  • September 2023
  • GlobalData
  • ID: 5649247
GSK plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GSK plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing general medicines, specialty medicines and vaccines. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular, and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GSK plc Key Recent Developments

  • Sep 14023: GSK and Save the Children Renew Award-Winning Partnership, With Focus on ‘Zero Dose’ Children Who Have Never Received a Vaccine
  • Sep 12023: CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
  • Aug 03023: New Research Published in Science Highlights Potential of a Naturally Occurring Bacterium to Help Eradicate Malaria
  • Aug 01023: CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • GSK plc - Key Facts
  • GSK plc - Key Employees
  • GSK plc - Key Employee Biographies
  • GSK plc - Major Products and Services
  • GSK plc - History
  • GSK plc - Company Statement
  • GSK plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
  • Joint Venture
Section 2 - Company Analysis
  • Company Overview
  • GSK plc - Business Description
  • Business Segment: Commercial operations
  • Overview
  • Performance
  • Geographical Segment: Rest of World
  • Performance
  • Geographical Segment: UK
  • Performance
  • Geographical Segment: US
  • Performance
  • R&D Overview
  • GSK plc - Corporate Strategy
  • GSK plc - SWOT Analysis
  • SWOT Analysis - Overview
  • GSK plc - Strengths
  • GSK plc - Weaknesses
  • GSK plc - Opportunities
  • GSK plc - Threats
  • GSK plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences, Power Financial Deals and Alliances
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • GSK plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 14, 2023: GSK and Save the Children Renew Award-Winning Partnership, With Focus on ‘Zero Dose’ Children Who Have Never Received a Vaccine
  • Sep 12, 2023: CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad Coverage
  • Aug 03, 2023: New Research Published in Science Highlights Potential of a Naturally Occurring Bacterium to Help Eradicate Malaria
  • Aug 01, 2023: CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
  • Jul 26, 2023: Strong Performance And Momentum Drive Upgraded Guidance
  • Jul 19, 2023: New Analysis Shows Lost Ground on Adult Immunisation During the Pandemic With 100 Million Doses Potentially Missed
  • Jun 27, 2023: Wood Wins Significant U.S. Life Sciences Project With GSK
  • Jun 05, 2023: Over $5 Million to Accelerate Cancer Research and Innovation in Quebec - Oncopole Strengthens Its Leadership Role in the Oncology Ecosystem With the Support of Numerous Partners
  • Jun 01, 2023: GSK announces the COiMMUNITY initiative to help achieve higher adult vaccination rates in the US
  • May 08, 2023: CureVac announces dosing of first participant in combined phase 1/2 study of multivalent, modified influenza vaccine candidates developed in collaboration with GSK
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • GSK plc, Key Facts
  • GSK plc, Key Employees
  • GSK plc, Key Employee Biographies
  • GSK plc, Major Products and Services
  • GSK plc, History
  • GSK plc, Other Locations
  • GSK plc, Subsidiaries
  • GSK plc, Joint Venture
  • GSK plc, Key Competitors
  • GSK plc, Ratios based on current share price
  • GSK plc, Annual Ratios
  • GSK plc, Interim Ratios
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • GSK plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • GSK plc, Performance Chart (2018 - 2022)
  • GSK plc, Ratio Charts
  • GSK plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • GSK plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Merck & Co Inc
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • AbbVie Inc
  • Eli Lilly and Co
  • Sanofi
  • Pfizer Inc
  • Gilead Sciences Inc
  • Amgen Inc
  • Novartis AG
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Sanofi
  • Pfizer Inc
  • Amgen Inc
  • Gilead Sciences Inc
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • AbbVie Inc
  • Revitin Life Sciences LLC
  • Novartis AG
  • Johnson & Johnson
  • Merck & Co Inc
  • F. Hoffmann-La Roche Ltd